AFFILIATIONS
1 Memorial Sloan Kettering Cancer Center, New York, New York, United States
2 Icahn School of Medicine at Mount Sinai, New York, New York, United States
3 Memorial Sloan Kettering Cancer Center, New York, New York, United States
4 Weill Cornell Medicine, New York, New York, United States
5 Memorial Sloan Kettering Cancer Center, New York, New York, United States
6 Memorial Sloan Kettering Cancer Center, New York, New York, United States
7 Memorial Sloan Kettering Cancer Center, New York, New York, United States
8 Memorial Sloan Kettering Cancer Center, New York, New York, United States
9 Memorial Sloan Kettering Cancer Center, New York, New York, United States
10 Memorial Sloan Kettering Cancer Center, New York, New York, United States
11 Memorial Sloan Kettering Cancer Center, New York, New York, United States
12 Memorial Sloan Kettering Cancer Center, New York, New York, United States
13 Memorial Sloan Kettering Cancer Center, New York, New York, United States
14 Memorial Sloan Kettering Cancer Center, New York, New York, United States
15 Memorial Sloan Kettering Cancer Center, New York, New York, United States
16 Memorial Sloan Kettering Cancer Center, New York, New York, United States
17 Memorial Sloan Kettering Cancer Center, New York, New York, United States
18 Memorial Sloan Kettering Cancer Center, New York, New York, United States
19 Memorial Sloan Kettering Cancer Center, New York, New York, United States
20 Memorial Sloan Kettering Cancer Center, New York, New York, United States
21 City of Hope, Duarte, United States
22 Memorial Sloan Kettering Cancer Center, New York, New York, United States
23 Memorial Sloan Kettering Cancer Center, New York, New York, United States
ABSTRACT
Development of CAR T cells targeting AML has been difficult due to challenges in identifying optimal tumor antigens, intrinsic alterations in T cell function, and a hostile tumor microenvironment. Here, we identify a specific population of disease-associated and tissue-restricted T regulatory cells (Tregs) enriched in the bone marrow of patients and mice with AML that suppress anti-tumor cytotoxicity. This motivated us to develop CAR T cells to selectively deplete this population of tumor-associated Tregs, which led to remodeling of the tumor microenvironment to promote anti-leukemic immunity and disease clearance while averting deleterious autoimmunity.
We analyzed > 50 blood and bone marrow samples from patients with AML and healthy controls with single cell approaches to identify new cell intrinsic and extrinsic immunotherapy strategies for AML. This included dedicated CITE-seq of Tregs purified from the bone marrow of patients with untreated AML (n=10) and MRD-positive (n=4) remission versus healthy subjects (n=6). These studies revealed the emergence of a phenotypically distinct tumor-associated CD4+ FoxP3+ Tregs in the bone marrow of patients with AML marked by increased surface expression of CCR8, CCR4, and TGFb family genes. The characteristic increased CCR8+ Tregs population identified in patients was conserved across syngeneic immunocompetent mouse models of AML including C57/B6 mice engrafted with mouse C1498 AML cells, as well as AML driven by KMT2A-rearrangement and the NrasG12D mutation or combined deletion of Tet2 and Trp53. In each model, CCR8+ Tregs were enriched in the bone marrow, but not peripheral blood, where their abundance correlated with degree of AML burden.
To test the therapeutic impact of depletion of CCR8+ and CCR4+ Tregs, we engineered third-generation CARs incorporating the natural ligands CCL17 and CCL21 (which bind CCR4) as well as CCL1 (which binds CCR8) for selective depletion of CCR4 or CCR8 expressing Tregs. While each CAR did not impact ex vivo growth of AML models lacking CCR4/8 expression, evaluation of each CAR T cell in C1498-bearing mice revealed that anti-CCR8 CAR T cells, in particular, substantially reduced CCR8+ bone marrow Tregs and conferred potent anti-tumor activity without reducing the abundance of CCR8- Tregs in the peripheral blood. Additionally, depletion of CCR8+ Tregs dramatically increased the frequency of effector CD8 and CD4 T cells in the bone marrow, while reducing naïve CD8 and CD4 T cells.
We next sought to further enhance the therapeutic modulation of the immune microenvironment by armoring each of our natural ligand-based CAR T cells with engineered IL-18 secretion. IL-18 armoring significantly improved both CAR T cell expansion in vivo as well as survival of C1498 AML-bearing mice relative to mice treated with CAR T cells lacking IL-18. IL-18 armored CCR8 targeting CAR T cells exhibited the strongest anti-leukemic activity of the CAR T cells tested and enabled mice surviving initial AML challenge to maintain immunologic memory upon secondary tumor cell challenge.
Given the therapeutic benefit of CAR-mediated CCR8 Treg depletion in mice, we next generated analogous third generation human CAR T cells targeting human CCR8 using human CCL1 as the CCR8 binder. To test the activity of these CARs, we developed an in vitro culture system wherein CD4+ CD25+ Tregs were generated in vitro from donor CD4+ T cells and then co-cultured with autologous CCR8-depleting CAR T cells generated from CD3+ T cells from the same donor. In this system, each CAR resulted in dose-dependent reduction in the CCR8+ Treg population without impacting Treg abundance otherwise. Ongoing work is evaluating the impact of these CAR T cells in immunocompetent mouse models humanized for CCR8 as well as in a human co-culture system including CAR T cells, Tregs, and AML cells.
Our cumulative data reveal that selective depletion of tumor-associated Tregs in the bone marrow of patients with AML rescues impaired anti-tumor immunity and by itself can improve anti-leukemic activity. These findings support the concept that AML is characterized by phenotypically distinct (CCR8+) tumor-associated Tregs that suppress endogenous anti-tumor activity. More broadly, these findings present a new strategy of utilizing CAR T cells to eliminate suppressors of endogenous immune function to promote eradication of AML and other cancers known to have tumor-associated Tregs.
DISCLOSURES
Bing-Yi Chen: No relevant conflicts of interest to declare.